Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.

被引：62

作者：

Gadgeel, Shirish M.

Stevenson, James

Langer, Corey J.

Gandhi, Leena

Borghaei, Hossein

Patnaik, Amita

Villaruz, Liza Cosca

Gubens, Matthew A.

Hauke, Ralph J.

Yang, James Chih-Hsin

Sequist, Lecia V.

Bachman, Robert D.

Ge, Joy Yang

Raftopoulos, Harry

Papadimitrakopoulou, Vassiliki

机构：

[1] Karmanos Canc Inst, Detroit, MI USA

[2] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA

[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[6] South Texas Accelerated Res Theraput, San Antonio, TX USA

[7] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA

[8] Univ Calif San Francisco, San Francisco, CA 94143 USA

[9] Nebraska Canc Specialists, Omaha, NE USA

[10] Natl Taiwan Univ Hosp, Taipei, Taiwan

[11] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[12] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[13] Harvard Med Sch, Boston, MA 02115 USA

[14] Merck & Co Inc, Kenilworth, NJ USA

[15] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.9016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9016

引用

页数：3

共 50 条

[1] Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.
Papadimitrakopoulou, Vassiliki
Patnaik, Amita
Borghaei, Hossein
Stevenson, James
Gandhi, Leena
Gubens, Matthew A.
Yang, James Chih-Hsin
Sequist, Lecia V.
Ge, Joy Yang
Bourque, Jennifer
Bachman, Robert D.
Im, Ellie
Gadgeel, Shirish M.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[2] Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H.
Gubens, Matthew A.
Sequist, Lecia V.
Stevenson, James
Powell, Steven Francis
Villaruz, Liza Cosca
Gadgeel, Shirish M.
Langer, Corey J.
Patnaik, Amita
Borghaei, Hossein
Jalal, Shadia Ibrahim
Fiore, Joseph
Ge, Joy Yang
Raftopoulos, Harry
Gandhi, Leena
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[3] Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407
Powell, S. F.
Rodriguez Abreu, D.
Langer, C. J.
Tafreshi, A.
Paz-Ares, L.
Kopp, H-G.
Rodriguez-Cid, J.
Kowalski, D.
Cheng, Y.
Kurata, T.
Awad, M. M.
Lin, J.
Zhao, B.
Pietanza, M. C.
Piperdi, B.
Garassino, M. C.
ANNALS OF ONCOLOGY, 2019, 30
[4] Pemetrexed-Carboplatin Plus Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update
Borghaei, H.
Langer, C.
Gadgeel, S.
Papadimitrakopoulou, V.
Patnaik, A.
Powell, S.
Gentzler, R.
Martins, R.
Stevenson, J.
Jalal, S.
Panwalkar, A.
Yang, J. C.
Gubens, M.
Sequist, L.
Awad, M.
Fiore, J.
Saraf, S.
Raftopoulos, H.
Gandhi, L.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1791 - S1791
[5] Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
Paz-Ares, L.
Langer, C. J.
Novello, S.
Halmos, B.
Cheng, Y.
Gadgeel, S. M.
Hui, R.
Sugawara, S.
Borghaei, H.
Cristescu, R.
Aurora-Garg, D.
Albright, A.
Loboda, A.
Kobie, J.
Lunceford, J.
Ayers, M.
Lubiniecki, G. M.
Pietanza, M. C.
Piperdi, B.
Garassino, M. C.
ANNALS OF ONCOLOGY, 2019, 30 : 917 - +
[6] First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.
Papadimitrakopoulou, Vassiliki
Gadgeel, Shirish M.
Borghaei, Hossein
Gandhi, Leena
Patnaik, Amita
Powell, Steven Francis
Gentzler, Ryan D.
Martins, Renato G.
Stevenson, James
Jalal, Shadia Ibrahim
Panwalkar, Amit W.
Yang, James Chih-Hsin
Gubens, Matthew A.
Sequist, Lecia V.
Awad, Mark M.
Fiore, Joseph
Ge, Joy Yang
Raftopoulos, Harry
Langer, Corey J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[7] Primary results from Japanese phase I study of pembrolizumab plus chemotherapy as front-line therapy for advanced NSCLC
Kurata, Takayasu
Nakagawa, Kazuhiko
Satouchi, Miyako
Seto, Takashi
Sawada, Takeshi
Han, Shi Rong
Noguchi, Kazuo
Shimamoto, Takashi
Nogami, Naoyuki
ANNALS OF ONCOLOGY, 2019, 30
[8] Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC
Borghaei, H.
Langer, C. J.
Gadgeel, S.
Papadimitrakopoulou, V. A.
Patnaik, A.
Powell, S. F.
Gentzler, R. D.
Martins, R. G.
Stevenson, J. P.
Jalal, S. I.
Panwalkar, A.
Yang, J. C-H.
Gubens, M.
Sequist, L.
Awad, M. M.
Fiore, J.
Saraf, S.
Raftopoulos, H.
Gandhi, L.
ANNALS OF ONCOLOGY, 2017, 28
[9] Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G
Langer, C.
Gaddgeel, S. M.
Borghaei, H.
Papadimitrakopoulou, V. A.
Patnaik, A.
Powell, S.
Gentzler, R. D.
Martins, R. G.
Stevenson, J. P.
Jalal, S. I.
Panwalkar, A.
Yang, J. C-H.
Gubens, M. A.
Sequist, L. V.
Awad, M. M.
Fiore, J. J.
Ge, Y.
Raftopoulos, H.
Gandhi, L.
ANNALS OF ONCOLOGY, 2016, 27
[10] Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.
Patnaik, Amita
Socinski, Mark A.
Gubens, Matthew A.
Gandhi, Leena
Stevenson, James
Bachman, Robert D.
Bourque, Jennifer
Ge, Joy Yang
Im, Ellie
Gadgeel, Shirish M.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →